Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > RPE65

RPE65

Brief Information

Name:Retinoid isomerohydrolase
Target Synonym:EC:5.3.3.22,Retinoid isomerohydrolase,All-trans-retinyl-palmitate hydrolase,Retinal pigment epithelium-specific 65 kDa protein,RPE65,RPE65, Retinoid Isomerohydrolase,Retinol Isomerase,Retinal Pigment Epithelium-Specific Protein 65kDa,EC 5.3.3.22,Retinoid Isomerohydrolase RPE65,Retinal Pigment Epithelium Specific Protein 65,EC 5.3.3.-,EC:3.1.1.64,Lutein Isomerase,Meso-Zeaxanthin Isomerase,BCO Family, Member 3,Retinitis Pigmentosa 20 (Autosomal Recessive),RBP-Binding Membrane Protein,EC 3.1.1.64,M
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product Inquiry

* We couldn't find what you're looking for. You can let us help by filling the form below. Our tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information will be kept strictly confidential.
Product inquiry collection form
*
*
*
*
*
*
*
*
*
ACRO Quality

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Voretigene neparvovec-rzyl 2SPI046IKD; rAAV.hRPE65v2; AAV2-hRPE65v2; SPKRPE-65; rAAV2-CBSB-hRPE65; AAV2.RPE65 Approved The Children'S Hospital Of Philadelphia Luxturna United States Retinal Dysplasia Spark Therapeutics Inc 2017-12-19 Vision Disorders; Retinal Dystrophies; Leber Congenital Amaurosis; Retinal Dysplasia Details
Voretigene neparvovec-rzyl 2SPI046IKD; rAAV.hRPE65v2; AAV2-hRPE65v2; SPKRPE-65; rAAV2-CBSB-hRPE65; AAV2.RPE65 Approved The Children'S Hospital Of Philadelphia Luxturna United States Retinal Dysplasia Spark Therapeutics Inc 2017-12-19 Vision Disorders; Retinal Dystrophies; Leber Congenital Amaurosis; Retinal Dysplasia Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Emixustat Hydrochloride ACU-02; ACU-4429; ACU-4429 HCl Phase 3 Clinical Acucela Inc Anetoderma; Geographic Atrophy; Stargardt Disease; Macular Degeneration; Diabetic Retinopathy Details
LX-101 LX-101 Phase 3 Clinical Shanghai Langsheng Biological Technology Co Ltd Retinal Dystrophies; Retinal Dysplasia; Retinal Degeneration Details
HORA-RPE65 (Horama) HORA-RPE65 Phase 2 Clinical Horama Sa Leber Congenital Amaurosis Details
HG-004 HG-004 Phase 2 Clinical HuiGene Therapeutics Ltd Leber Congenital Amaurosis; Retinal Diseases Details
Emixustat Hydrochloride ACU-02; ACU-4429; ACU-4429 HCl Phase 3 Clinical Acucela Inc Anetoderma; Geographic Atrophy; Stargardt Disease; Macular Degeneration; Diabetic Retinopathy Details
LX-101 LX-101 Phase 3 Clinical Shanghai Langsheng Biological Technology Co Ltd Retinal Dystrophies; Retinal Dysplasia; Retinal Degeneration Details
HORA-RPE65 (Horama) HORA-RPE65 Phase 2 Clinical Horama Sa Leber Congenital Amaurosis Details
HG-004 HG-004 Phase 2 Clinical HuiGene Therapeutics Ltd Leber Congenital Amaurosis; Retinal Diseases Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message